Benchmark Cuts Omnicell (NASDAQ:OMCL) Price Target to $40.00

Omnicell (NASDAQ:OMCL) had its price objective reduced by Benchmark from $62.00 to $40.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also commented on OMCL. Wells Fargo & Company reduced their price target on Omnicell from $38.00 to $31.00 and set an “equal weight” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $45.83.

Omnicell Stock Performance

Shares of Omnicell stock opened at $25.88 on Wednesday. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.75. The stock’s fifty day moving average price is $32.28 and its 200-day moving average price is $39.96. The firm has a market cap of $1.21 billion, a P/E ratio of 95.86, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. The firm had revenue of $269.67 million during the quarter, compared to analysts’ expectations of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.03 EPS. On average, equities research analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently modified their holdings of the stock. New Age Alpha Advisors LLC acquired a new position in shares of Omnicell in the first quarter valued at about $233,000. Arkadios Wealth Advisors raised its stake in shares of Omnicell by 7.5% during the 1st quarter. Arkadios Wealth Advisors now owns 46,705 shares of the company’s stock worth $1,633,000 after buying an additional 3,251 shares during the period. XTX Topco Ltd raised its position in Omnicell by 316.1% during the first quarter. XTX Topco Ltd now owns 30,295 shares of the company’s stock worth $1,059,000 after acquiring an additional 23,015 shares during the period. GSA Capital Partners LLP purchased a new position in Omnicell in the 1st quarter valued at about $901,000. Finally, Pacer Advisors Inc. purchased a new position in shares of Omnicell in the first quarter valued at approximately $10,542,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.